Nasrien E Ibrahim1, Cian P McCarthy2, Shreya Shrestha2, Hanna K Gaggin1, Renata Mukai2, Jackie Szymonifka3, Fred S Apple4, John C Burnett5, Seethalakshmi Iyer5, James L Januzzi6. 1. Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 2. Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. 3. New York University Langone Medical Center, New York, New York. 4. Laboratory Medicine & Pathology, Hennepin County Medical Center & University of Minnesota, Minneapolis, Minnesota. 5. Mayo Clinic, Rochester, Minnesota. 6. Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Baim Institute for Clinical Research, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.
Abstract
BACKGROUND: With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether change in BNP concentrations is similar across all assays for its measurement. Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are unknown. Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP1-108, or C-type natriuretic peptide (CNP) is not well understood. OBJECTIVES: This study sought to examine the effects of sacubitril/valsartan on results from different natriuretic peptide assays. METHODS: Twenty-three consecutive stable patients with heart failure and reduced ejection fraction were initiated and titrated on sacubitril/valsartan. Change in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP1-108, and CNP were measured over 3 visits. RESULTS: Average time to 3 follow-up visits was 22, 46, and 84 days. ANP rapidly and substantially increased with initiation and titration of sacubitril/valsartan, more than doubling by the first follow-up visit (+105.8%). Magnitude of ANP increase was greatest in those with concentrations above the median at baseline (+188%) compared with those with lower baseline concentrations (+44%); ANP increases were sustained. Treatment with sacubitril/valsartan led to inconsistent changes in BNP, which varied across methods assessed. Concentrations of MR-proANP, NT-proBNP, and proBNP1-108 variably declined after treatment; whereas CNP concentrations showed no consistent change. CONCLUSIONS: Initiation and titration of sacubitril/valsartan led to variable changes in concentrations of multiple natriuretic peptides. These results provide important insights into the effects of sacubitril/valsartan treatment on individual patient results, and further suggest the benefit of neprilysin inhibition may be partially mediated by increased ANP concentrations.
BACKGROUND: With sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether change in BNP concentrations is similar across all assays for its measurement. Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are unknown. Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP1-108, or C-type natriuretic peptide (CNP) is not well understood. OBJECTIVES: This study sought to examine the effects of sacubitril/valsartan on results from different natriuretic peptide assays. METHODS: Twenty-three consecutive stable patients with heart failure and reduced ejection fraction were initiated and titrated on sacubitril/valsartan. Change in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP1-108, and CNP were measured over 3 visits. RESULTS: Average time to 3 follow-up visits was 22, 46, and 84 days. ANP rapidly and substantially increased with initiation and titration of sacubitril/valsartan, more than doubling by the first follow-up visit (+105.8%). Magnitude of ANP increase was greatest in those with concentrations above the median at baseline (+188%) compared with those with lower baseline concentrations (+44%); ANP increases were sustained. Treatment with sacubitril/valsartan led to inconsistent changes in BNP, which varied across methods assessed. Concentrations of MR-proANP, NT-proBNP, and proBNP1-108 variably declined after treatment; whereas CNP concentrations showed no consistent change. CONCLUSIONS: Initiation and titration of sacubitril/valsartan led to variable changes in concentrations of multiple natriuretic peptides. These results provide important insights into the effects of sacubitril/valsartan treatment on individual patient results, and further suggest the benefit of neprilysin inhibition may be partially mediated by increased ANP concentrations.
Authors: Emily K Zern; Susan Cheng; Aaron M Wolfson; Michele A Hamilton; Michael R Zile; Scott D Solomon; Michelle M Kittleson Journal: Circ Heart Fail Date: 2020-02-14 Impact factor: 8.790
Authors: Juan Brignone; Kasper Bostlund Assersen; Mia Jensen; Boye L Jensen; Brian Kloster; Morten Jønler; Lars Lund Journal: Pflugers Arch Date: 2021-04-12 Impact factor: 3.657
Authors: Nicholas Y Tan; Yihong Deng; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah; Andrew D Rule; John C Burnett; Shannon M Dunlay; S Jeson Sangaralingham Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-02-15
Authors: Jens P Goetze; Benoit G Bruneau; Hugo R Ramos; Tsuneo Ogawa; Mercedes Kuroski de Bold; Adolfo J de Bold Journal: Nat Rev Cardiol Date: 2020-05-22 Impact factor: 32.419
Authors: Erica M Dillon; Shouzuo D Wei; Deepak K Gupta; Hui Nian; Brooks S Rodibaugh; Katherine N Bachmann; Allen J Naftilan; Lynne W Stevenson; Nancy J Brown Journal: J Card Fail Date: 2021-06-13 Impact factor: 5.712
Authors: Valentina Cannone; Mark Ledwidge; Chris Watson; Paul M McKie; John C Burnett; Kenneth McDonald Journal: JACC Basic Transl Sci Date: 2021-06-16